Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
This marks the second indication for which gumokimab has gained NDA review acceptance
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated